• Facets (new session)
• Description
• Metadata
• Settings
  • Rule: ActivityStreamsMapasEquivalentb3sb3sifpdbprdf-labelfacetshttp://dbpedia.org/resource/inference/rules/dbpedia#http://dbpedia.org/resource/inference/rules/opencyc#http://dbpedia.org/resource/inference/rules/umbel#http://dbpedia.org/resource/inference/rules/yago#http://dbpedia.org/schema/property_rules#http://www.ontologyportal.org/inference/rules/SUMO#http://www.ontologyportal.org/inference/rules/WordNet#http://www.w3.org/2002/07/owl#ldpoplwebskos-transurn:det:rdf:labelvirtrdf-labelvirtrdf-urlNone
    
  • Inverse Functional Properties: Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects
  • "Same As": Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects (recommended) Apply to subjects, objects and predicates (not recommended on big datasets) Apply to predicates only (special use cases only)

About: Brasofensine     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : umbel-rc:DrugProduct, within Data Space : dbpedia.demo.openlinksw.com associated with source document(s)

Type: Thingdul:ChemicalObjectchemical substanceDrugyago:WikicatOximesyago:WikicatStimulantsyago:Abstraction100002137yago:AliphaticCompound114601294yago:Amine114739004yago:Chemical114806838yago:Cognition100023271yago:Compound114818238yago:Information105816287yago:Material114580897yago:Matter100020827yago:MethaneSeries114951377yago:OrganicCompound114727670yago:Oxime114972092yago:Part113809207yago:PhysicalEntity100001930yago:PsychologicalFeature100023100yago:Relation100031921drugyago:Stimulation105827684yago:Substance100019613yago:WikicatSympathomimeticAminesumbel-rc:DrugProduct New Facet based on Instances of this Class

Brasofensine (NS-2214, BMS-204756) is a phenyltropane that had been under development by Bristol-Myers Squibb for the treatment of Parkinson's and Alzheimer's diseases. In animal models of Parkinson's disease, brasofensine was effective in stimulating LMA and reversing akinesia. Phase II trials in humans were conducted in 1996 and brasofensine was shown to be both effective and well tolerated at a dose of 4 mg; however, development was stopped after in vivo cis-anti isomerization of the 2α-methyloxime group was reported.